{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.220","value":"7.64"},{"groupId":"OG001","spread":"19.041","value":"6.67"},{"groupId":"OG002","spread":"24.296","value":"10.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"Cycle 5, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.541","value":"8.33"},{"groupId":"OG001","spread":"28.294","value":"12.04"},{"groupId":"OG002","spread":"21.995","value":"1.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 9, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.644","value":"4.76"},{"groupId":"OG001","spread":"19.003","value":"-1.67"},{"groupId":"OG002","spread":"15.516","value":"2.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 13, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.546","value":"2.78"},{"groupId":"OG001","spread":"30.008","value":"6.94"},{"groupId":"OG002","spread":"21.570","value":"4.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 17, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.434","value":"12.50"},{"groupId":"OG001","spread":"33.333","value":"0.00"},{"groupId":"OG002","spread":"20.412","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"Cycle 21, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.797","value":"14.58"},{"groupId":"OG001","spread":"11.785","value":"-8.33"},{"groupId":"OG002","spread":"5.893","value":"-4.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Cycle 25, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.667","value":"16.67"},{"groupId":"OG001","spread":"11.785","value":"-8.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 29, Day 1"},{"categories":[{"measurements":[{"comment":"Not estimable due to sample size","groupId":"OG000","spread":"NA","value":"0.00"},{"comment":"Not estimable due to sample size","groupId":"OG001","spread":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 33, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.045","value":"7.74"},{"groupId":"OG001","spread":"26.917","value":"-14.93"},{"groupId":"OG002","spread":"17.678","value":"20.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Safety Follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"Mean change from baseline at safety follow-up visit in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes global health status and quality of life questions related to their overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a higher score indicating improved health status.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG000","title":"Cohort 1: ENKTL"},{"description":"Participants with other R/R mature T-cell neoplasms \\[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG001","title":"Cohort 2: PTCL-NOS, AITL, and ALCL"},{"description":"Participants with R/R cutaneous T-cell lymphoma \\[limited to mycosis fungoides (MF) and Sèzary syndrome (SS)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG002","title":"Cohort 3: MF and SS"}],"paramType":"MEAN","populationDescription":"Safety analysis set includes all participants who received at least one dose of study drug. The number analyzed represents participants who completed the questionnaire.","reportingStatus":"POSTED","timeFrame":"Baseline and on Day 1 in Cycles 5, 9, 13, 17, 21, 25, 29, and 33 (21 days per cycle) and safety follow-up visit (up to 30 days after end of treatment; up to approximately 3 years and 1 week)","title":"Quality of Life Assessment: EORTC QLQ-C30 Change From Baseline in Global Health Status Score","type":"SECONDARY","unitOfMeasure":"Score on a scale"}